Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
A Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Background Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone. This may be true for many types of cancer, including castration-resistant prostate cancer (CRPC). Objective To test if the combination of the drugs BN-brachyury, …

androgen ablation
blood test
solid tumor
flutamide
androgens
  • 21 views
  • 22 Oct, 2022
  • 1 location
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001) (PRESERVE-001)

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

pd-l1
ovarian cancer
hysterectomy
sarcoma
antibody therapy
  • 34 views
  • 25 Oct, 2022
  • 34 locations
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors

A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC

metastasis
cancer chemotherapy
pembrolizumab
endobronchial ultrasound
  • 0 views
  • 07 Oct, 2022
  • 2 locations
Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)

Exacerbations of asthma and COPD are an important cause of hospital admission and the main cause of annual winter bed shortages. Despite current guideline treatment with prednisolone, 40% of patients require further treatment, 15% are readmitted and, of those hospitalised, 10% die within 3 months, all by definition treatment failures. …

  • 12 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 25 Oct, 2022
  • 1 location
Wake Forest Alzheimer's Disease Clinical Core (ADCC)

reduce amyloid burden and toxicity, while also directly enhancing synaptic health, brain metabolism, tau regulation and neurovascular function. The purpose of the ADCC is to identify and

mini-mental state examination
amyloidosis
cognitive impairment
Accepts healthy volunteers
mental deterioration
  • 11 views
  • 07 Jul, 2022
  • 1 location
Lung Function Exercise Capacity and Serology Responses in Patients With COVID-19

(a) Objectives To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. To assess the longevity of the serology response to SARS-CoV2. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using …

  • 0 views
  • 02 Sep, 2021
  • 1 location
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.

dinutuximab
high-risk neuroblastoma
  • 0 views
  • 07 Oct, 2022
  • 14 locations
Alzheimer's Disease Core Center (ADCC)

The main objective of this research project is to provide a comprehensive clinical database of patients with Alzheimer's disease (AD) and other forms of dementia, individuals with mild cognitive impairment (MCI), and age-matched normal controls. The study will also attempt to identify cognitively normal individuals at genetically defined risk for …

alzheimer's disease
mild cognitive impairment
cognitive impairment
Accepts healthy volunteers
dementia
  • 69 views
  • 25 Jan, 2022
  • 1 location
Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA) (GALA)

antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and antibody-mediated complement activation, are conditioned by the structure of the crystallizable

arthritis
autoimmune disease
anti-dna antibodies
vasculitis
lupus
  • 0 views
  • 07 Oct, 2022
  • 2 locations